MRC1 and neoplasm: We also observed a reduction in the number of pro-tumorigenic M2 phenotypic (CD206+) macrophages and an increase in tumoricidal M1 phenotypic (CD80+) macrophages in the spleen, lymph node, and tumor with the combination treatment.